Top of this page
Skip navigation, go straight to the content
Our new five-year collaboration with the UK @epilepsysociety aims to address needs of people with epilepsy who do not respond to currently available treatments. Find out more about it here: https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics
— UCB News (@ucb_news) 18.02.2019
#Epilepsy is the most common serious neurological condition, affecting more than half a million people in the UK. That is why UCB is collaborating with @epilepsysociety to address this problem. https://t.co/p1Rr0oqLEO #ProudPartners #HarnessingGenetic
— UCB News (@ucb_news) 14.02.2019
Find out more about our new genomic partnership with the UK @epilepsysociety – which follows UCB’s commitment to invest £1 billion into the UK life-sciences sector over the next five years. https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics #
— UCB News (@ucb_news) 13.02.2019